investigation
SIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.
A investigation by 先聲藥業集團. Statements are as reported by the cited publishers — not verified by DecisionGateway.
已獲國家藥品監督管理局批准在中國開展臨牀試驗
Discussion
Related claims
SIM0725 was independently developed by the company.先聲藥業集團 · statementSIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).先聲藥業集團 · statementSIM0725 is intended for the treatment of autoimmune diseases.先聲藥業集團 · statementNovo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and semaglutide injection) for long-term weight management has been accepted by the National Medical Products Administration.诺和诺德 · statementCagriSema is a fixed-dose combination formulation.界面新闻 · statementCagriSema consists of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.界面新闻 · statement
More claims by 先聲藥業集團
SIM0725 was independently developed by the company.statementSIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).statementSIM0725 is intended for the treatment of autoimmune diseases.statement
All claims by 先聲藥業集團